KOR

e-Article

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Document Type
Article
Source
In Annals of Oncology December 2023 34(12):1131-1140
Subject
Breast tumor
Language
ISSN
0923-7534